EXOZYMES INC. (EXOZ) Form 10-Q — Aug 13, 2026
eXoZymes (EXOZ) filed its Q2 2026 10-Q with no revenue and a net loss of $2.88 million for the quarter, 22% wider than the $2.36 million loss a year earlier; the first-half net loss reached $5.25 million versus $4.22 million in the prior-year period, driven by an 85.7% jump in R&D costs and lower grant offsets.
Key figures
- Revenue
- 0
- Total Assets
- 7982355
- Cash Position
- 5652696
- Shares Outstanding
- 9281359
- Ga costs h1 2026
- 2781698
- Rd costs h1 2026
- 2559166
- Stock comp h1 2026
- 1720037
- Nsf cfire grant share
- 3000000
- June 2026 net proceeds
- 5861147
- June 2026 shares issued
- 732260
- Net loss yoy pct change
- 24.5
- Offering price per unit
- 18
- June 2026 gross proceeds
- 6590340
- June 2026 warrants issued
- 366130
- Mdb capital ownership pct
- 46.4
- Shelf registration capacity
- 50000000
- Working capital jun 30 2026
- 4550841
- Warrant liability jun 30 2026
- 1902612
- Antidilutive securities shares
- 3138306
- Investor warrant exercise price
- 11.24
Price after filing
1 day: -3.0%7 days: +17.3%30 days: +5.0%
Close on the filing date to close N calendar days later (from $6.00). Historical, not a forecast.
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.